Boothbay Fund Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Boothbay Fund Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-189,292	Closed	-$1.91M	–	2698
2022 Q4	$1.91M	Sell	189,292 -5,942	-3%	-$59.5K	0.04%	613
2022 Q3	$1.94M	Sell	195,234 -128,569	-40%	-$1.27M	0.05%	585
2022 Q2	$3.21M	Buy	323,803 +238,910	+281%	+$2.34M	0.08%	358
2022 Q1	$837K	Buy	+84,893	New	+$836K	0.02%	1013

Boothbay Fund Management's BIOT Position: Q1 2023 in Review

Boothbay Fund Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 189,292 shares — an estimated $1.91M sold.

Boothbay Fund Management first reported a position in BIOT in Q1 2022 and held it in 4 quarters. The position peaked at $3.21M in Q2 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Boothbay Fund Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Boothbay Fund Management sold 189,292 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $1.91M.
Boothbay Fund Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2022 and held it in 4 quarters.
Boothbay Fund Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $3.21M in Q2 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Boothbay Fund Management's 13F filing for Q1 2023, filed 15 May 2023.